Elevance Health stock trades near recent highs as strong 2024 guidance follows double digit earnings growth

Elevance Health Inc. (ISIN US2855211023) delivered double digit earnings growth in 2023, and Elevance Health stock continues to trade near recent highs as the S&P 500 health insurer backs that performance with firm 2024 guidance and ongoing share repurchases, according to the company's latest filings and investor materials.

EPS up more than 10 percent

Elevance Health is one of the largest U.S. managed care and health benefits companies, and its recent financial reporting underpins the current valuation of Elevance Health stock. According to the company's 2023 annual reporting and subsequent investor presentations, Elevance Health generated adjusted earnings per share in 2023 that were more than 10% higher than in 2022, reflecting the impact of premium growth, membership expansion, and operating discipline. The insurer has highlighted that earnings expansion as a core pillar of its medium term value-creation story, contrasting the double digit EPS growth with a mid single digit revenue trend.

In the same set of disclosures, Elevance Health reported billions of dollars in operating cash flow for 2023, providing the funding base for dividends and buybacks. The group emphasized that this cash generation supports a balanced capital deployment framework that includes reinvestment in health services and technology as well as direct returns to shareholders. By linking higher earnings per share with strong cash flow, Elevance Health aims to show investors that its business model is resilient even as U.S. health policy and Medicaid redeterminations introduce volatility into membership numbers.

Revenue growth and guidance for 2024

On the top line, Elevance Health reported total operating revenue in 2023 in the tens of billions of dollars, with a year on year increase versus 2022 that remained in the mid single digit percentage range. The company attributed this revenue growth to expansion in its commercial and government programs businesses, alongside contributions from its Carelon health services unit. By pairing revenue growth with a higher rate of EPS growth, Elevance Health signaled to investors that margins are improving and that the mix of business is shifting toward higher value services.

Looking out to 2024, Elevance Health has issued guidance that implies another year of double digit adjusted earnings per share growth. Management has described a target range in which 2024 adjusted EPS is expected to grow at a low double digit rate compared with 2023, reflecting ongoing margin initiatives, cost-control measures, and the continued scaling of Carelon. This guidance gives Elevance Health stock a clear forward earnings narrative, and investors can compare the guided growth against the prior year's more than 10% EPS expansion to gauge the sustainability of the trend.

Dividend and buybacks support returns

Beyond earnings and revenue, Elevance Health places considerable emphasis on shareholder returns. According to recent investor communications from the company, Elevance Health paid an annual dividend in 2023 that represented a low payout ratio relative to adjusted earnings, leaving significant room for reinvestment and share repurchases. The dividend level was increased compared with the prior year, continuing a multi year pattern of stepwise raises that signal confidence in long term cash flows.

In parallel, Elevance Health executed substantial share buybacks in 2023, retiring a notable fraction of its outstanding shares. The company's capital deployment summary indicates that these repurchases, measured in billions of dollars, contributed meaningfully to the more than 10% growth in adjusted earnings per share versus 2022, because the combination of rising earnings and a smaller share count amplified the EPS metric. For Elevance Health stock, this buyback activity matters because it can provide downside support when market volatility increases and can enhance per share value even if revenue growth moderates.

Carelon segment drives higher value services

A core pillar of Elevance Health's strategy is the expansion of its Carelon health services segment, which encompasses pharmacy benefit management, behavioral health, and other clinical and administrative services. In the latest financial disclosures, the company highlighted that Carelon contributed a growing share of total operating revenue in 2023, with segment revenue increasing at a faster percentage rate than the consolidated group. While exact figures vary across sub segments, Elevance Health emphasized that higher margin service lines within Carelon are helping to lift overall profitability.

Management has communicated that investment in Carelon will continue in 2024, with resources allocated to data analytics, care management platforms, and value based care initiatives. The strategic aim is to use Carelon's capabilities to improve outcomes for Elevance Health members and clients, thereby supporting premium rates and reducing medical cost trends over time. For Elevance Health stock, the growth trajectory of Carelon serves as an important differentiator compared with peers that rely more heavily on insurance underwriting alone.

Medical cost trend and membership dynamics

Like other managed care companies, Elevance Health must balance premium growth with medical cost trend. In recent reporting, the company described a medical loss ratio for 2023 that remained within its targeted range, indicating that claims costs stayed aligned with expectations. The combination of disciplined pricing and care management was presented as a key factor in keeping the medical loss ratio under control, even as inflation affected certain cost categories and utilization patterns shifted.

Membership trends in 2023 were influenced by Medicaid redeterminations, which led to a reduction in enrollment in certain government programs. However, Elevance Health reported offsetting gains in some commercial and Medicare lines, along with new accounts for Carelon. The company guided that 2024 membership will reflect the full year impact of redeterminations but expects underlying demand for managed care and health services to remain robust. This nuanced membership picture is important context for Elevance Health stock, because it shows that headwinds in one segment can be partially mitigated by growth in others.

Balance sheet and capital structure

Elevance Health's balance sheet metrics are another component of its investment case. The company's filings show total debt in the tens of billions of dollars at the end of 2023, alongside substantial cash and investments. Management has stressed that leverage remains within a targeted range that supports the company's credit ratings, and that interest coverage ratios are healthy thanks to strong operating earnings. This capital structure allows Elevance Health to fund acquisitions and organic investment while continuing dividends and buybacks.

Rating agencies have generally maintained stable outlooks on Elevance Health's debt, reflecting both the scale of its cash flows and the defensive characteristics of health insurance. The company's ability to refinance maturities and access capital markets at reasonable spreads is an important backdrop for Elevance Health stock, especially during periods when interest rate volatility affects investor sentiment toward leveraged issuers. By underscoring balance sheet resilience, Elevance Health seeks to reassure equity investors that its capital deployment plans rest on a solid financial foundation.

Elevance Health revenue up mid single digits

The revenue trend is central to understanding the trajectory of Elevance Health stock. In its 2023 reporting, the company indicated that total operating revenue rose by a mid single digit percentage compared with 2022, driven by both premium increases and growth in health services. That mid single digit revenue growth, combined with more than 10% growth in adjusted earnings per share, suggests that Elevance Health is improving its operating margin and shifting toward higher value offerings.

For 2024, Elevance Health's guidance implies that revenue will continue to grow, albeit potentially at a rate similar to or slightly above the 2023 mid single digit increase. While the company has not promised outsized top line expansion, it has emphasized that disciplined underwriting, cost management, and the scaling of Carelon should support further margin improvement. Investors in Elevance Health stock can therefore focus on how the balance between revenue growth and earnings growth evolves, and whether the company can sustain low double digit EPS increases on the back of mid single digit revenue gains.

Elevance Health products and services

Elevance Health's product portfolio spans health insurance and services offerings across commercial, individual, Medicare, Medicaid, and specialty lines. On the insurance side, the company provides medical plans to employers of various sizes as well as individual and family coverage, often marketed under regional brands in states where it operates Blue Cross Blue Shield plans. These products generate premium revenue that forms the core of Elevance Health's operating revenue.

In addition to traditional insurance products, Elevance Health offers pharmacy benefit management, behavioral health, and other clinical and administrative services through its Carelon unit. These services are sold to health plans, employers, and government programs, and they help clients manage medical costs and improve outcomes. Elevance Health has reported that revenue from such services is growing faster than the overall group, indicating that clients are increasingly willing to pay for integrated solutions that leverage data, analytics, and coordinated care. This shift toward services is a key strategic theme underlying the long term story of Elevance Health stock.

Elevance Health stock and market context

Elevance Health stock is listed on the New York Stock Exchange and is included in the S&P 500 index, positioning it among the major U.S. health insurers followed by institutional investors. As of a recent trading day in 2024, shares have traded near their 52 week high, reflecting the market's recognition of the company's double digit earnings growth and disciplined capital returns. While the exact share price fluctuates day to day, the proximity to the yearly high levels underscores that investors currently assign a premium valuation compared with periods when regulatory or cost uncertainties weighed more heavily on sentiment.

For retail investors, the main drivers of Elevance Health stock in coming quarters are likely to be the company's ability to deliver on its 2024 guidance for low double digit adjusted EPS growth, the evolution of medical cost trend and membership, and the progress of Carelon's expansion. The balance between returning cash to shareholders through dividends and buybacks and investing in new capabilities will also matter. Elevance Health's current financial metrics suggest that it has room to pursue both, but disappointing execution on any of these fronts could cause the stock to move away from recent highs. Conversely, successful delivery and further margin improvement would help support the existing valuation.